⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 15, 2025Open Access

Figure S9 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer

Tianyu Qu Lei Song Jiali Xu Xiyi Lu Dandan Yin Jiali Dai Chen Zhang Renhua Guo Erbao Zhang

View Full Paper

Ask AI

Bookmark

Share

Key Points

MYLK-AS1 enhances resistance to EGFR inhibitors in non-small cell lung cancer through glutamine metabolism, suggesting therapeutic implications.
The study shows that MYLK-AS1 increases the stability of GLUD1 mRNA, impacting resistance mechanisms in cancer treatment.
Assessment reveals a direct binding relationship between MYLK-AS1 and ILF3, enhancing GLUD1 mRNA stability in cancer cells.
These findings highlight potential targets for overcoming treatment resistance in non-small cell lung cancer.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

MYLK-AS1 enhances glutamine metabolism in non-small cell lung cancer, indicating a role in EGFR inhibitor resistance.

Abstract

MYLK-AS1 enhances the stability of GLUD1 mRNA by directly binding to ILF3.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qu et al. (2025) studied this question.

synapsesocial.com/papers/68af59d2ad7bf08b1eade1ed https://doi.org/10.1158/0008-5472.29919033

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S10 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
2Figure S8 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
3Figure S7 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
4Figure S5 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
5Figure S11 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025